Biomerica (NASDAQ:BMRA) Announces Quarterly Earnings Results

Biomerica (NASDAQ:BMRA) released its earnings results on Wednesday. The company reported ($0.45) earnings per share for the quarter, Zacks reports. Biomerica had a negative return on equity of 73.44% and a negative net margin of 74.84%.

Biomerica Stock Down 0.7%

Shares of NASDAQ BMRA traded down $0.02 during midday trading on Wednesday, reaching $2.69. 5,938 shares of the company’s stock traded hands, compared to its average volume of 28,049. The company has a market cap of $7.94 million, a price-to-earnings ratio of -2.80 and a beta of 0.11. The stock’s 50 day simple moving average is $2.47 and its 200-day simple moving average is $2.87. Biomerica has a one year low of $2.11 and a one year high of $10.16.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biomerica in a report on Tuesday, October 14th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Biomerica has a consensus rating of “Sell”.

About Biomerica

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.